HOPKINTON, Mass., May 26, 2020 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated dosing patients in a Phase 1 trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist. “Working with our principal investigators in the United States, we are thrilled to announce that we have been able to deliver SB 11285 intravenously to the first patient in our Phase I trial of advanced solid tumors,” said Atif Abbas, M.D., Vice President & Head of Oncology/Immunology Development at Spring Bank.
HOPKINTON, Mass., Feb. 14, 2020 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.
Top Ranked Momentum Stocks to Buy for December 24th
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 26.) Aimmune Therapeutics Inc (NASDAQ: AIMT ...
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Top Ranked Momentum Stocks to Buy for December 11th
As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.
The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors. During the fourth quarter of 2019, Spring Bank dosed the first patient in the monotherapy dose escalation component of the intravenously-administered SB 11285 Phase 1a trial.
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8 - 12, 2019 in Kauai, Hawaii. “We are excited to present impressive data on our chimeric antisense oligonucleotide (CASO) program in HBV, including our preclinical candidate, SB 527, at HepDART 2019,” commented Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer of Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). In addition, the company has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV. The decision to stop the dosing of inarigivir 400mg in the Phase 2b CATALYST trials was due to clinical findings observed in the CATALYST 2 trial of virally-suppressed chronic HBV patients.
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has discontinued development of inarigivir soproxil, which was in Phase 2 development for the treatment of chronic hepatitis B virus (HBV). This decision was made in the interest of patient safety based on the occurrence of unexpected serious adverse events, including one patient death, in Spring Bank’s Phase 2b CATALYST trial.
Q3 2019 Spring Bank Pharmaceuticals Inc Earnings Call
Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing.
Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today provided an update on the company’s business operations in response to and as a result of the global COVID-19 pandemic. The company has taken steps to protect the safety of its employees while working to ensure the sustainability of its business operations and development programs as the COVID-19 pandemic continues to evolve.
Companies In The News Are: QGEN, IMMU, CANF, SBPH
HOPKINTON, Mass., May 20, 2020 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.